Pharmacokinetics of Doxycycline and Tissue Concentrations of an Experimental Long-acting Parenteral Formulation of Doxycycline in Wistar Rats

Abstract

Doxycycline hyclate (CAS 24390-14-5, doxycycline-h), an antibacterial with time-dependent action, was formulated as a non-irritating long-acting parenteral formulation based on a β-cyclodextrin: poloxamer-based matrix (doxycycline-h-LA). Tissue and serum concentrations vs time profile were investigated after its subcutaneous injection to Wistar rats. Serum concentration profiles and key pharmacokinetic (PK) variables of doxycycline-h-LA were compared to the corresponding profiles and PK values obtained with an aqueous formulation of doxycycline-h administered either intramuscularly, orally or intravenously to Wistar rats. In all groups, the dose was 10 mg/kg. Doxycycline-h-LA showed outstanding bioavailability (951% or 477% if a correction formula is considered), as compared to the one obtained with an aqueous formulation (106-82%, respectively). Corresponding values for maximum serum concentration were 3.19 µg/ml and 3.00 µg/ml, respectively, and elimination half-lives were completely different: 42.49 h and 2.77 h for doxycycline-h-LA and the aqueous formulation, respectively. Considering minimal inhibitory concentrations of doxycycline for sensitive and resistant bacteria (from ≤ 0.5 to ≥1.5 µg/ml), doxycycline-h-LA could be injected every 2 or 3 days, while aqueous doxycycline-h would require a dosing interval from 7.5 to 11 h. But if tissue concentrations are taken as braking points, the dosing interval will vary from 48 to 94 h. For doxycycline-h-LA, mean tissue:serum ratios were 2:1 for lungs, 9.8:1 for kidneys and 2.2:1 for intestine homogenates. These values are in close agreement with those found for the distribution of doxycycline in other species.

Key words

Antibacterials - CAS 24390-14-5 - Doxycycline, pharmacokinetics, rat, sustained-release

• References

• 1 Suzuka I, Kaji H, Kaji A. Binding of specific sRNA to 30S ribosomal subunits: effects of 50S ribosomal subunits. Proc Natl Acad Sci USA. 1966; 55: 1483-1486
• 2 Craig W. Pharmacokinetic-pharmacodynamic parameters: rationale for antibiotic use in mice and men. Clin Infect Dis. 1998; 6: 1-12
• 3 Ole-Mapenay IM, Mitema ES, Mathio TE. Aspects of pharmacokinetics of doxycycline given to healthy and pneumonic east African dwarf goats by intramuscular injection. Vet Res Commun. 1997; 21: 453-62
• 4 Chopra I, Howe TGB, Linton KB, Richmond MH, Speller DCE. The tetracyclines: prospects at the beginning of the 1980s. J Antimicrob Chemother. 1981; 8: 5-21
• 5 Cunha BA, Sibley CM, Ristuccia AM. Doxycycline. Ther Drug Monit. 1982; 4: 115-135
• 6 Prescott JF, Baggot JD, Walker RD. Antimicrobial Therapy in Veterinary Medicine. 3rd ed Ames (Iowa, USA): Iowa State University Press, Blackwell Scientific Publications; 2000. p 275-289
• 7 Vomand KC, Sumano LH. Adverse drug reactions in cattle. JAVMA. 1990; 197: 899-905
• 8 Meijer LA, Ceyssens KGF, De Greve BI, De Bruijn W. Pharmacokinetics and bioavailability of doxycycline hyclate after oral administration in calves. Vet Q. 1993; 15: 15-
• 9 Riond JL, Tyezkowska K, Riviere JE. Pharmacokinetics and metabolic inertness of doxycycline in calves with mature or immature rumen function. Am J Vet Res. 1989; 50: 1329-1332
• 10 Riond JL, Vaden SL, Riviere JE. Comparative pharmacokinetics of doxycycline in cats and dogs. J Vet Pharmacol Ther. 1990; 13: 415-24
• 11 Ziv G, Sulman FG. Analysis of pharmacokinetic properties of nine tetracycline analogues in dairy cow and ewes. Am J Vet Res. 1974; 35: 1197-201
• 12 Bousquet E, Pommier P, Wessel-Robert S, Morvan H, Benoit-Valiergue H, Laval A. Efficacy of doxycycline in feed for the control of pneumonia caused by Pasteurella multocida and Mycoplasma hyopneumoniae in fattening pigs. Vet Rec. 1998; 143: 269-
• 13 Abd AM, Aty EL, Goudaha A, Zhoub HH. Pharmacokinetics of doxycycline after administration as a single intravenous bolus and intramuscular doses to non-lactating Egyptian goats. Pharmacol Res. 2004; 49: 487-491
• 14 Ole-Mapenay IM, Mitema ES. Some pharmacokinetic parameters of doxycycline in east African goats after intramuscular administration of a long acting formula. Vet Res Commun. 1995; 19: 425-32
• 15 Schach Von Wittenau M, Twomey TM. The disposition of doxycycline by man and dog. Chemotherapy. 1971; 16: 217-228
• 16 Whelton A, Schach von Wittenau M, Twomey TM, Walker WG, Bianchine JR. Doxycycline pharmacokinetics in the absence of renal function. Kidney Int. 1974; 5: 365-371
• 17 Baumueller A, Madsen PO. Secretion of various antimicrobial substances in dogs with experimental bacterial prostatitis. Urol Res. 1977; 5: 215-218
• 18 laffe JM, Poust RI, Feld SL, Colaizzi JL, Jaffe JM, Colaizzi JL, Poust RI. Influence of repetitive dosing and altered urinary pH on doxycycline excretion in humans. J Pharm Sci. 1974; 8: 1256-1260
• 19 Bekers O, Uijtendaal EV, Beijnen JH, Bult A, Underberg WJM. Cyclodextrins in the pharmaceutical field. Drug Dev Ind Pharm. 1991; 17: 1503-1549
• 20 Lawrence MJ. Surfactant systems microemulsions and vesicles as vehicles for drug delivery. Eur J Drug Metab Pharmacokinet. 1994; 19: 257-259
• 21 Bennett JV, Brodie JL, Benner EJ, Kirby WM. Simplified, accurate method for antibiotic assay of clinical specimens. J Appl Microbiol. 1966; 14: 170-177
• 22 Cinquina AL, Longo F, Anastasi G, Giannetti L, Cozzani R. Validation of a high-performance liquid chromatography method for the determination of oxytetracycline, tetracycline, chlortetracycline and doxcycline in bovine milk and muscle. J Chromatogr A. 2003; 987: 227-233
• 23 Welling PG. Pharmacokinetics, Processes, Mathematics and applications. 2nd ed Washington DC: American Chemical Society; 1997. p 11-34
• 24 Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed New York: Marcel Dekker; 1982. p 409
• 25 Brayden DJ. Novel drug delivery strategies in veterinary medicine. Irish Vet J. 2003; 56: 310-316
• 26 Cunha BA, Domenico P, Cunha CB. Pharmacodynamics of Doxycycline. Clin Microbiol Infect. 2000; 6: 270-273
• 27 Yeruham I, Perl S, Sharony D, Vishinisky Y. Doxycycline toxicity in calves in two feedlots. J Vet Med B. 2002; 49: 406-408
• 28 Chiers K, Weyens P, Deprez P, Van Heerden M, Meulemans G, Baert K, Croubles S, De Backer P, Ducatelle R. Lingual and pharyngeal paralysis due to acute doxycycline intoxication in veal calves. Vet Rec. 2004; 155: 25-26
• 29 Inskeep PB, Darrington RT. Utilization of biopharmaceutical and pharmacokinetic principles in the development of veterinary controlled release drug delivery systems. In Rathbone MJ, Gurny R. editors Controlled Release Veterinary Drug Delivery. Amsterdam: Elsevier Science; 2000. p 1-15
• 30 Shaw DH, ST Rubin. Pharmacologic activity of doxycycline. J Am Vet Med Assoc. 1986; 189: 808-810
• 31 Barza M, Brown RB, Shanks C, Gamble C, Weinstein L. Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline and oxytetracycline in dogs. Antimicrob Agents Chemother. 1975; 8: 713-720
• 32 Brook I, Elliott TB, Pryor HI, Sautter TE, Gnade BT, Thakar JH, Knudson GB. In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int J Antimicrob Agents. 2001; 18: 559-562
• 33 Hospenthal DR, Murray CK. In vitro susceptibilities of seven Leptospira species to traditional and newer antibiotics. Antimicrob Agents Chemother. 2003; 47: 2646-2648
• 34 Guerin-Faublee V, Flandrois JP, Broye E, Tupin F, Richard Y. Actinomyces pyogenes: susceptibility of 103 clinical animal isolates to 22 antimicrobial agents. Vet Res. 1993; 24: 251-259
• 35 Jee JB, Degraves FJ, Kim TY, Kaltenboeck B. High prevalence of natural chlamydophila species infection in calves. J Clin Microbiol. 2004; 42: 5664-5672
• 36 Yoshimura H, Ishimura M, Endoh YS, Kojima A. Antimicrobial susceptibility of Pasteurella multocida isolated from cattle and pigs. J Vet Med. 2001; 48: 555-560
• 37 Notari RE. Principles of pharmacokinetics: dosage regimen. In Notari RE. editor Biopharmaceutics and clinical pharmacokinetics - an introduction,. 4th ed New York: M. Dekker; 1987. p 45-212
• 38 Riond JL, Riviere JE. Pharmacokinetics and toxicology of doxycycline. Vet Hum Toxicol. 1988; 30: 431-444
• 39 Toutain PL, Bousquet-Mélou A. Bioavailability and its assessment. J Vet Pharmacol Ther. 2004; 27: 455-466
• 40 Vu XG, Nix DE, Gillikin S, Schentag GJ. Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline. Antimic Agent Chemother. 1989; 33: 4-436